The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F09%3A5677" target="_blank" >RIV/00216208:11110/09:5677 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/09:5677 RIV/00023736:_____/09:00008622 RIV/00216208:11310/09:10107327

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus

Original language description

Diabetes mellitus is associated with a number of prothrombotic abnormalities, and correction of these abnormalities might translate into the reduction of cardiovascular risk. Glitazones improve endothelial function and reduce inflammation, but much lessis known about their effect on thrombogenic factors. We have therefore studied the effect of rosiglitazone on leukocyte and soluble thrombogenic markers in patients with type 2 diabetes mellitus. We observed substantial improvement in the expression of thrombogenic markers on leukocytes after rosiglitazone treatment, suggesting the novel antithrombotic effects of rosiglitazone.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FB - Endocrinology, diabetology, metabolism, nutrition

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2009

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Physiological Research

ISSN

0862-8408

e-ISSN

—

Volume of the periodical

58

Issue of the periodical within the volume

5

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

7

Pages from-to

—

UT code for WoS article

000272080200011

EID of the result in the Scopus database

—